<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00189254</url>
  </required_header>
  <id_info>
    <org_study_id>1524-IMIQ</org_study_id>
    <nct_id>NCT00189254</nct_id>
  </id_info>
  <brief_title>A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ</brief_title>
  <official_title>A Follow-up Study to Evaluate Actinic Keratosis Recurrence Rates One Year After Completion of the 1487-IMIQ Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MEDA Pharma GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MEDA Pharma GmbH &amp; Co. KG</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to obtain recurrence rates and long-term safety data for patients
      who had been treating actinic keratoses on the face and scalp with 5 % Imiquimod Cream in a
      previous study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <study_type>Observational</study_type>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>one year after completion of study 1487-Imiq</time_frame>
    <description>Efficacy was evaluated by counting AK lesions in the previous treatment area. Subjects at the 1-year follow-up visit with recurrence of lesion(s).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>one year after completion of study 1487-Imiq</time_frame>
    <description>Safety was evaluated by assessing the area of previous treatment for LSRs and skin quality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>one year after completion of study 1487-Imiq</time_frame>
    <description>AEs considered by investigator to be possibly or probably related to the 1487-Imiq study medication were documented and recorded.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment>72</enrollment>
  <condition>Actinic Keratoses</condition>
  <arm_group>
    <arm_group_label>Imiquimod 5% cream</arm_group_label>
    <description>No investigational treatments were given during this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod</intervention_name>
    <description>No defined treatments were given during this study.</description>
    <arm_group_label>Imiquimod 5% cream</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        At least 18 years old. Females of childbearing potential, with a negative urine pregnancy
        test, must have been willing to use a medically acceptable method of contraception during
        the treatment.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  100% clearance of Actinic Keratosis (AK) lesions in the 1487 IMIQ study

        Exclusion Criteria:

          -  used any treatments in the previous treatment area within 24 hours prior to the
             follow-up visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Coordinator</last_name>
    <role>Study Chair</role>
    <affiliation>Fundaci√≥ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>November 28, 2016</last_update_submitted>
  <last_update_submitted_qc>November 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>1 year follow up</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

